NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$75.26

-2.03 (-2.63%)

(As of 12/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $73.58
▼
$78.18
50-Day Range: $39.94
▼
$77.29
52-Week Range: $20.63
▼
$80.87

Volume: 1.08 million shs
Average Volume: 1.34 million shs
Market Capitalization: $3.27 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $111.55

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 48.2% Upside
$111.55 Price Target
Short Interest: Bearish
19.51% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 0.17
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.42) to ($3.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

126th out of 1,023 stocks

Pharmaceutical Preparations Industry

47th out of 501 stocks

4.5

Analyst's Opinion

Consensus Rating
Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $111.55, Axsome Therapeutics has a forecasted upside of 48.2% from its current price of $75.26.
Amount of Analyst Coverage
Axsome Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
19.51% of the float of Axsome Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Axsome Therapeutics has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Axsome Therapeutics has recently increased by 8.99%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Axsome Therapeutics does not currently pay a dividend.
Dividend Growth
Axsome Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Axsome Therapeutics has received a 69.68% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.
Environmental Sustainability
The Environmental Impact score for Axsome Therapeutics is -0.87.

2.9

News and Social Media Coverage

News Sentiment
Axsome Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Axsome Therapeutics this week, compared to 5 articles on an average week.
Search Interest
60 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.
MarketBeat Follows
22 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.00% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.96% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.42) to ($3.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axsome Therapeutics is -18.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axsome Therapeutics is -18.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axsome Therapeutics has a P/B Ratio of 183.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

November 30, 2022 | marketbeat.com

Struggling Axsome Stock Could Bounce Back on Drug Trial Success

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

December 5, 2022 | americanbankingnews.com

Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Price Target at $111.55

December 3, 2022 | americanbankingnews.com

FY2022 EPS Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Reduced by Cantor Fitzgerald

December 2, 2022 | finance.yahoo.com

Axsome Therapeutics Stock: Bear vs. Bull

December 2, 2022 | americanbankingnews.com

Axsome Therapeutics (NASDAQ:AXSM) PT Raised to $86.00

December 1, 2022 | americanbankingnews.com

Axsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $85.00 by Analysts at SVB Leerink

November 30, 2022 | msn.com

Axsome Therapeutics's Return On Capital Employed Insights

November 30, 2022 | americanbankingnews.com

Axsome Therapeutics (NASDAQ:AXSM) Stock Rating Reaffirmed by Mizuho

November 28, 2022 | msn.com

$1000 Invested In This Stock 5 Years Ago Would Be Worth $13,000 Today

November 28, 2022 | marketwatch.com

Axsome Therapeutics Shares Hit 52-Week High, Propelled by Alzheimer's Study >AXSM

November 28, 2022 | msn.com

Axsome Therapeutics Unusual Options Activity

November 28, 2022 | benzinga.com

Thinking about trading options or stock in Axsome Therapeutics, Sarepta Therapeutics, Las Vegas Sands, Apple, or Microsoft?

November 28, 2022 | marketwatch.com

Axsome Shares Rally Premarket on Alzheimer's Agitation Study Success >AXSM

November 28, 2022 | seekingalpha.com

Axsome says candidate for Alzheimer’s agitation met main goal in late-stage trial

November 28, 2022 | finance.yahoo.com

3 Growth Stocks to Buy That Could Skyrocket

November 28, 2022 | finance.yahoo.com

Want to Double Your Money? Buying These Stocks Could be a Genius Move

November 28, 2022 | finance.yahoo.com

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

November 28, 2022 | finance.yahoo.com

Axsome Therapeutics Investigational Drug Lowers Risk Of Agitation Relapse In Alzheimer's Patients

November 24, 2022 | finance.yahoo.com

Prediction: This Growth Stock Could Double in 2023

November 24, 2022 | seekingalpha.com

Axsome: Strong Earnings Signal More Upside

November 23, 2022 | finance.yahoo.com

Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 20, 2022 | finance.yahoo.com

Got $500? 3 Growth Stocks to Buy That Could Double Your Money

November 11, 2022 | finance.yahoo.com

Is Axsome Therapeutics Stock a Buy Now?

November 11, 2022 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

November 10, 2022 | finance.yahoo.com

Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its Third-Quarter Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings: 11/08/2021
Today: 12/06/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AXSM
CUSIP: N/A
CIK: 1579428
Web: axsome.com
Phone: (212) 332-3241
Fax: 212-320-0245
Employees: 108
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $111.55
High Stock Price Forecast: $210.00
Low Stock Price Forecast: $80.00
Forecasted Upside/Downside: +48.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-130,400,000.00
Net Margins: N/A
Pretax Margin: -622.89%
Return on Equity: -312.00%
Return on Assets: -90.97%

Debt

Debt-to-Equity Ratio: 0.60
Current Ratio: 4.19
Quick Ratio: 4.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 183.56

Miscellaneous

Outstanding Shares: 43,426,000
Free Float: 32,135,000
Market Cap: $3.27 billion
Optionable: Optionable
Beta: 1.86

Key Executives

Dr. Herriot Tabuteau M.D. (Age 54)
Founder, Chairman, CEO & Pres
Comp: $1.06M

Mr. Nick Pizzie CPA (Age 47)
M.B.A., Chief Financial Officer
Comp: $553.97k

Mr. Mark L. Jacobson (Age 39)
COO & Sec.
Comp: $554.72k

Mr. Hunter Murdock Esq.
Exec. VP of Legal & Compliance

Dr. Amanda Jones Pharm.D. (Age 39)
Sr. VP of Clinical Devel.

Ms. Lori Englebert M.B.A. (Age 44)
Exec. VP of Commercial & Bus. Devel.

Mr. Kevin Laliberte Pharm.D. (Age 44)
Exec. VP of Product Strategy

Joseph Debrah-Afful CPA
M.B.A., Director of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.
What is Axsome Therapeutics' stock price forecast for 2023?: 10 equities research analysts have issued 12 month price objectives for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $80.00 to $210.00. On average, they expect the company's stock price to reach $111.55 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.
How have AXSM shares performed in 2022?: Axsome Therapeutics' stock was trading at $37.78 at the start of the year. Since then, AXSM stock has increased by 99.2% and is now trading at $75.26.
View the best growth stocks for 2022 here.
When is Axsome Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AXSM earnings forecast.
How were Axsome Therapeutics' earnings last quarter?: Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.02. During the same quarter in the previous year, the business posted ($0.58) earnings per share.
What other stocks do shareholders of Axsome Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?: (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
What is Axsome Therapeutics' stock symbol?: Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
Who are Axsome Therapeutics' major shareholders?: Axsome Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.17%), BlackRock Inc. (5.05%), RTW Investments LP (4.33%), PFM Health Sciences LP (3.82%), Citadel Advisors LLC (0.00%) and State Street Corp (1.64%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends.
How do I buy shares of Axsome Therapeutics?: Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Axsome Therapeutics' stock price today?: One share of AXSM stock can currently be purchased for approximately $75.26.
How much money does Axsome Therapeutics make?: Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.27 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis.
How many employees does Axsome Therapeutics have?: The company employs 108 workers across the globe.
How can I contact Axsome Therapeutics?: Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Axsome Therapeutics - AXSM Stock Forecast, Price & News

Axsome Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Axsome Therapeutics (NASDAQ:AXSM) Stock

AXSM Stock News Headlines

AXSM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AXSM Stock - Frequently Asked Questions

Overall MarketRank^™